Depakote ER in Borderline Personality Disorder
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00222482 |
Recruitment Status :
Completed
First Posted : September 22, 2005
Last Update Posted : August 9, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Borderline Personality Disorder | Drug: Depakote ER | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 15 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | A Double-Blind and Placebo Controlled Assessment of Depakote ER in Borderline Personality Disorder |
Study Start Date : | March 2003 |
Actual Study Completion Date : | September 2005 |

- Symptom Checklist 90
- Barratt Impulsivity Scale

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:Male or female patients with the diagnosis of borderline personality disorder between the ages of 21 adn 55 years old. Must be in good physical health -
Exclusion Criteria:Major psychiatric illness on Axis I - schizophrenia or bipolar disorder. May not have current MDD. May not be dependent on illicit substances or alcohol.
-

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00222482
Principal Investigator: | Sellamnn C Schulz, M.D. | Department of Psychiatry, University of Minnesota Medical School |
ClinicalTrials.gov Identifier: | NCT00222482 |
Other Study ID Numbers: |
0306M49703 M009946 |
First Posted: | September 22, 2005 Key Record Dates |
Last Update Posted: | August 9, 2007 |
Last Verified: | August 2007 |
Borderline Personality Disorder |
Disease Personality Disorders Borderline Personality Disorder Pathologic Processes Mental Disorders Valproic Acid Anticonvulsants Enzyme Inhibitors |
Molecular Mechanisms of Pharmacological Action GABA Agents Neurotransmitter Agents Physiological Effects of Drugs Antimanic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs |